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In this paper, we investigate an HIV model incorporating the effect of an ARV regimen.
Since drug concentration varies during dose intervals, which results in periodic variation of
the drug eﬃcacy, our model is then a periodic time-dependent system. We get a threshold
value between the extinction and the uniform persistence of the disease by applying
the persistence theory. Our main results show that the disease goes to extinction if the
threshold value is less than unity, whilst the disease persists if the threshold value is
larger than unity. We also prove that there exists a positive periodic solution which
is globally asymptotically stable. The threshold dynamics is in agreement with that for the
system with constant coeﬃcients, which extends the classic results for the corresponding
autonomous model.
© 2009 Elsevier Inc. All rights reserved.
1. Introduction
Human Immunodeﬁciency Virus and Acquired Immune Deﬁciency Syndrome (AIDS) have received much attention from
public for their high speed of spread around the world. The process of an HIV infection is as follows. Firstly, HIV enters the
body, and cells with CD4 receptors become its targets, inside which it makes a DNA copy of its viral RNA in the presence
of the enzyme reverse transcriptase (RT). After that, HIV falls into the class of so-called retroviruses. Then the viral DNA
is inserted into the DNA of the T cell, following that the T cell produces viral particles to infect other uninfected T cells.
Finally, the body will be susceptible to opportunistic infections due to the loss of humoral and cellular immune function. The
current therapy for HIV consists primarily of the simultaneous administration of two or more antiretroviral drugs, potential
inhibitors of HIV replication in-vivo. These drugs are primarily drawn from two major classes, reverse transcriptase inhibitors
(RTIs) which block transcription of viral RNA into DNA, preventing the infection of new cells, and protease inhibitors (PIs),
which prevent protein cleavage in new virions, resulting in infected cells producing only noninfectious virus.
The early basic mathematical model studying HIV pathogenesis in-host incorporated healthy and infected CD4+ T cells
and HIV virions, and described interactions of the immune system and the virus [1,2]. Some useful information (i.e., in-
fected cell lifespan, viral clearance rate, bud rate of virions from infected cells) can be got regarding the pathogenesis of
HIV in-host from this basic model. Drug eﬃcacy that inhibits infection and the budding of HIV virions is assumed to be
constant in viral dynamics by Perelson and Nelson [4,6], Nelson et al. [17], Ding and Wu [20,21]. Early in 1999, Perelson
and Nelson established an HIV model incorporating RTIs [6], and considered the drug eﬃcacy nrt less than one. The model
equations are
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⎪⎪⎪⎪⎪⎪⎩
dT
dt
= λ − dT + rT
(
1− T
Tmax
)
− (1− nrt)kT V ,
dT ∗
dt
= (1− nrt)kT V − δT ∗,
dV
dt
= NδT ∗ − cV ,
(1.1)
where T (t), T ∗(t) and V (t) represent the concentration of uninfected target T cells, productively infected T cells and virus
at time t , respectively. λ, d, δ, N , c are positive constants, and λ is the source of CD4+ T cells from precursors. d is the
natural death rate of CD4+ T cells. δ is the death rate of infected cells. c is the viral clearance rate constant. N (burst size)
is the total number of virus particles released by a productively infected cell over its lifespan with mean 1/δ. k is the rate
of infection of T cells with free virus. The proliferation of the T cells is included as a logistic function in which r is the
maximum proliferation rate and Tmax is the T cell population density at which proliferation shuts off. The authors in [6]
assumed that the patient was in quasi-steady state before treatment began, and they concluded that if an RT inhibitor
was given, i.e., nrt > 0, then the only posttreatment steady state was the origin, moreover, this “uninfected” posttreatment
steady state was stable.
In system (1.1) drug eﬃcacy nrt is assumed to be a constant coeﬃcient. Drug concentration, however, varies during
the dose intervals. In fact, once a dose is administered, drug concentration gets high rapidly and reaches a peak value. As
time passes by, the concentration gets lower. When another dose is administered, drug concentration varies in the same
way [18]. Thus, drug concentration varies periodically on the long-term dynamics, which results in periodic variation of
the drug eﬃcacy nrt(t). The relationship between drug eﬃcacy and plasma concentration has been formulated by Huang
et al. [19]. Denote (1−nrt(t))k in (1.1) by a periodic function, say, K (t) in our model below. For simplicity, we do not include
the logistic term for dynamics of uninfected T cells. So the model equations are as follows.⎧⎪⎪⎪⎪⎪⎪⎨
⎪⎪⎪⎪⎪⎪⎩
dT
dt
= λ − dT − K (t)T V ,
dT ∗
dt
= K (t)T V − δT ∗,
dV
dt
= NδT ∗ − cV ,
(1.2)
where K (t) = k(1 − nrt(t)) is a nonnegative and periodic function with period ω (ω > 0). Assume 1ω
∫ ω
0 K (t)dt > 0. Other
constants λ, d, δ, N , and c are the same as those in system (1.1).
Our model, based on the basic model of HIV pathogenesis in-host, incorporates the periodic variation of drug eﬃcacy
(reverse transcriptase). The main purpose of this paper is to investigate the threshold value (or the basic reproduction
number) which governs whether the disease dies out or not, and further to examine the relationship between the threshold
value obtained here and that for the corresponding system with constant coeﬃcients.
This paper is organized as follows. In the next section, we investigate threshold dynamics of system (1.2). In particular,
we examine the threshold value, and study the global stability of the disease-free equilibrium and the uniform persistence
of the system (1.2). In Section 3 we concentrate on the existence and stability of the positive periodic solution. In the ﬁnal
section, we give the conclusions and discussions for further work.
2. Threshold dynamics
It is obvious that any solution of system (1.2) with nonnegative initial values is nonnegative. The following proposition
shows that solutions of system (1.2) are uniformly and ultimately bounded.
Proposition 2.1. The solutions of system (1.2) are uniformly and ultimately bounded, i.e., there exist an M > 0, and T>0 such that
(T (t), T ∗(t), V (t)) (M,M,M), for t  T .
Proof. By the ﬁrst and second equations of system (1.2), we get
d(T + T ∗)
dt
= λ − dT − δT ∗  λ −min{d, δ}(T + T ∗).
Then the comparison theorem implies that there exists t1 > 0 such that T (t) + T ∗(t)  λ/min{d, δ}, for t  t1. Let M1 =
max{λ/d, λ/δ}, then T (t) M1, T ∗(t) M1, for t  t1.
By the third equation of (1.2), we get for t  t1, V˙  NδM1 − cV . Then the comparison theorem implies that there exists
T  t1 such that V (t) NδM1/c, for t  T .
Let M = max{M1,NδM1/c}, then it follows that T (t)  M , T ∗(t)  M , V (t)  M , t  T . Thus solutions of (1.2) are
uniformly and ultimately bounded. This completes the proof. 
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globally asymptotically stable. We denote T¯ = λ/d for convenience in what follows. Before giving the theorem and the proof
of global stability of the disease-free equilibrium, we introduce the following preliminaries.
Let (Rn, Rn+) be the standard ordered n-dimensional Euclidean space with a norm ‖.‖. For u, v ∈ Rn , we denote u  v , if
u − v ∈ Rn+; u > v , if u − v ∈ Rn+\{0}; and u  v , if u − v ∈ Int(Rn+). Consider A(t) is a continuous, cooperative, irreducible
and periodic n × n matrix function with period ω, ω > 0. Let ΦA(.)(t) be the fundamental solution matrix of the linear
ordinary differential equation
x˙ = A(t)x. (2.1)
Let r(ΦA(.)(ω)) be the spectral radius of ΦA(.)(ω). By the Perron–Frobenius theorem, r(ΦA(.)(ω)) is the principal eigenvalue
of ΦA(.)(ω), in the sense that it is simple and admits an eigenvector v∗  0. We present a useful result for our next
arguments from paper [5].
Lemma 2.1. Let μ = 1ω ln r(ΦA(.)(ω)). Then there exists a positive, ω-periodic function v(t) such that eμt v(t) is a solution of
x˙ = A(t)x.
Deﬁne a matrix
M1(t) =
(−δ λd K (t)
Nδ −c
)
,
which will be used to prove the extinction and the uniform persistence of the disease.
Theorem 2.1. If r(ΦM1(.)(ω)) < 1, then the disease-free equilibrium of system (1.2), i.e., E1(
λ
d ,0,0), is globally asymptotically stable.
Proof. Firstly, we illustrate the disease-free steady state E1 is locally stable.
The Jacobian matrix of system (1.2) at E1 equals⎛
⎝
−d 0 0
0 −δ λd K (t)
0 Nδ −c
⎞
⎠=
(−d 0
0 M1(t)
)
.
Since e−dω < 1, and r(ΦM1(.)(ω)) < 1, then it follows that E1 is locally stable.
We now prove the global attractivity of the disease-free steady state E1.
By the ﬁrst equation of system (1.2) and nonnegativity of the solutions, we get T˙  λ − dT . Then ∀ > 0, there exists
t˜ > 0, such that T (t) T¯ +  , t  t˜ .
Consider an auxiliary system⎧⎪⎪⎨
⎪⎪⎩
dTˆ ∗
dt
= K (t)(T¯ + )Vˆ − δ Tˆ ∗,
dVˆ
dt
= Nδ Tˆ ∗ − cVˆ ,
(2.2)
which is equivalent to(
Tˆ ∗
Vˆ
)′
= M1(t)
(
Tˆ ∗
Vˆ
)
+ M2(t)
(
Tˆ ∗
Vˆ
)
,
where
M2(t) =
(
0 K (t)
0 0
)
.
It follows from Lemma 2.1 that there exists a positive ω-periodic function v(t) = (v1(t), v2(t)) such that eμ1t v(t) is a
solution of (2.2), where μ1 = 1ω ln r(ΦM1(.)+M2(.)(ω)). Choose t¯ > t˜ and a small number α > 0 such that
Tˆ ∗(t¯) αv1(0), Vˆ (t¯) αv2(0).
Thus we get
Tˆ ∗(t) αeμ1(t−t¯)v1(t − t¯), Vˆ (t) αeμ1(t−t¯)v2(t − t¯), t  t¯.
By the comparison principle we get
T ∗(t) Tˆ ∗(t) αeμ1(t−t¯)v1(t − t¯), V (t) Vˆ (t) αeμ1(t−t¯)v2(t − t¯), t  t¯.
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r(ΦM1(.)+M2(.)(ω)) < 1. Hence, we get μ1 < 0. It follows that Tˆ ∗(t) → 0, Vˆ (t) → 0, as t → ∞. Then we get
lim
t→∞ T
∗(t) = 0, lim
t→∞ V (t) = 0.
By the ﬁrst equation of system (1.2), we get
lim
t→∞ T (t) = T¯ .
Thus it follows limt→∞(T (t)− T¯ ) = 0, limt→∞ T ∗(t) = 0, limt→∞ V (t) = 0. Hence, the disease-free steady state E1 is globally
attractive.
By the local stability and global attractivity of E1, we get the disease-free equilibrium of system (1.2), E1, is globally
asymptotically stable. This completes the proof. 
Theorem 2.2. If r(ΦM1(.)(ω)) > 1, the system (1.2) is uniformly persistent, i.e., there exists a positive constant ε, such that for all initial
values (T0, T ∗0 , V0) ∈ R+ × Int(R2+), the solution of (1.2) satisﬁes lim inft→∞(T (t), T ∗(t), V (t)) (ε, ε, ε).
Let X be a metric space, f : X → X be a continuous map, and X0 ⊂ X be an open set. Deﬁne
∂ X0 := X\X0, M∂ :=
{
x ∈ ∂ X0: f n(x) ∈ ∂ X0, n 0
}
. (2.3)
A∂ is a maximal compact invariant set of f in ∂ X0. A ﬁnite sequence {M1, . . . ,Mk} are disjoint, compact, and invariant
subsets of ∂ X0, and each of them is isolated in ∂ X0. For the convenience of description, we present the following persistence
theory [3, Theorem 1.3.1].
Lemma 2.2. Assume that
(C1) f (X0) ⊂ X0 and f has a global attractor A;
(C2) The maximal compact invariant set A∂ = A ∩ M∂ of f in ∂ X0 , possibly empty, admits a Morse decomposition {M1, . . . ,Mk}
with the following properties:
(a) Mi is isolated in X.
(b) Ws(Mi) ∩ X0 = ∅ for each 1 i  k.
Then there exists δ > 0 such that for any compact internally chain transitive set L with L  Mi for all 1  i  k, we have
infx∈L d(x, ∂ X0) > δ, that is to say, f : X → X is uniformly persistent with respect to (X0, ∂ X0).
Proof of Theorem 2.2. Let us deﬁne
X = R3+, X0 = R+ × Int
(
R2+
)
, ∂ X0 := X\X0.
Deﬁne Poincaré map P : R3+ → R3+ , satisfying P (x0) = u(ω, x0), ∀x0 ∈ R3+ , with u(t, x0) the unique solution of (1.2) satisfying
u(0, x0) = x0.
Firstly, we show that P is uniformly persistent with respect to (X0, ∂ X0). It is easy to see from system (1.2) that X
and X0 are positively invariant. Moreover, ∂ X0 is a relatively closed set in X . It follows from Proposition 2.1 that solutions
of (1.2) are uniformly and ultimately bounded. Thus the semiﬂow P is point dissipative on R3+ , and P : R3+ → R3+ is compact.
By [16, Theorem 3.4.8], it then follows that P admits a global attractor, which attracts every bounded set in R3+.
Deﬁne
M∂ =
{(
T0, T
∗
0 , V0
) ∈ ∂ X0: Pm(T0, T ∗0 , V0) ∈ ∂ X0, ∀m 0}.
Next, we claim that
M∂ =
{
(T ,0,0): T  0
}
.
In fact, it is obvious that
{
(T ,0,0): T  0
}⊆ M∂ .
For any (T0, T ∗0 , V0) ∈ ∂ X0\{(T ,0,0): T  0}, if T ∗0 = 0, V0 > 0, then by the second equation of (1.2), we have
T˙ ∗(0) = K (0)T (0)V (0) > 0;
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V˙ (0) = NδT ∗(0) > 0.
This implies that for t > 0 suﬃciently small, (T , T ∗, V ) /∈ ∂ X0, then (T , T ∗, V ) /∈ M∂ . That is to say, for any (T0, T ∗0 , V0) /∈{(T ,0,0): T  0}, (T0, T ∗0 , V0) /∈ M∂ . It indicates that M∂ ⊆ {(T ,0,0): T  0}. Therefore M∂ = {(T ,0,0): T  0}.
Clearly, E1 is one ﬁxed point of P in M∂ . If (T , T ∗, V ) is a solution of system (1.2) initiating from M∂ , it then follows
from system (1.2) that T (t) → T¯ , T ∗(t) → 0, V (t) → 0 as t → ∞.
In the following we shall show that if the invariant set E1 is isolated, then {E1} is an acyclic covering. To do this, it needs
to prove any solution of system (1.2) initiating from M∂ will remain into M∂ , which can be obtained easily. The isolated
invariance of E1 will follow proof.
We now show that Ws(E1) ∩ X0 = ∅. Denote x0 = (T0, T ∗0 , V0) ∈ X0. By the continuity of solutions with respect to the
initial values, ∀ > 0 there exists δ0 > 0 such that for all x0 ∈ X0 with ‖x0 − E1‖ δ0, it follows∥∥u(t, x0)− u(t, E1)∥∥ , ∀t ∈ [0,ω].
We now claim that
limsup
m→∞
d
(
Pm
(
x0
)
, E1
)
 δ0.
Suppose not, then
limsup
m→∞
d
(
Pm
(
x0
)
, E1
)
< δ0,
for some x0 ∈ X0. Without loss of generality, we can assume that
d
(
Pm
(
x0
)
, E1
)
< δ0, ∀m > 0.
Then we have
∥∥u(t, Pm(x0))− u(t, E1)∥∥ , ∀t ∈ [0,ω].
For any t  0, let t =mω + t′, where t′ ∈ [0,ω] and m = [ tω ] is the greatest integer less than or equal to tω . Thus, we get∥∥u(t, x0)− u(t, E1)∥∥= ∥∥u(t′, Pm(x0))− u(t′, E1)∥∥< , ∀t  0.
Let (T (t), T ∗(t), V (t)) = u(t, x0). It follows that 0 T ∗(t)  , 0 V (t) . Then by the ﬁrst equation of (1.2) we get
T˙ (t) λ − dT − K (t)T .
Consider an auxiliary equation
˙ˆT (t) = λ − dTˆ − K (t)Tˆ . (2.4)
For any  > 0, system (2.4) admits a globally asymptotically stable solution Tˆ (0, ), where Tˆ (0, ) = λ ∫∞0 e−ds ×
e−
∫ s
0 K (t−σ)dσ ds. Then for any ξ > 0, there exists t1 > 0 such that Tˆ (t, )  Tˆ (0, ) − ξ for t  t1, Tˆ (t, ) is any solution
of Eq. (2.4). Note that Tˆ (0, ) → T¯ as  → 0. Then for any η¯ > 0 there exists ¯ > 0 such that Tˆ (0, ) T¯ − η¯ for  < ¯ . It
follows that for t  t1 and  small enough ( < ¯)
Tˆ (t, ) Tˆ (0, ) − ξ  T¯ − η¯ − ξ  T¯ − η.
It follows from Eq. (2.4) and comparison principles that T (t) Tˆ (t, ) T¯ − η, for t  t1 and  small enough.
Consider another auxiliary system⎧⎪⎪⎨
⎪⎪⎩
dT˘ ∗
dt
= K (t)T¯ V˘ − δ T˘ ∗ − ηK (t)V˘ ,
dV˘
dt
= Nδ T˘ ∗ − cV˘ .
(2.5)
For convenience, we will rewrite (2.5) as
d
dt
(
T˘ ∗(t)
V˘ (t)
)
= (M1(t) − ηM2(t))
(
T˘ ∗(t)
V˘ (t)
)
.
It follows from Lemma 2.1 that there exists a positive ω-periodic function p(t) = (p1(t), p2(t)) such that eμ2t p(t) is a
solution of (2.5), where μ2 = 1 ln r(ΦM1(.)−ηM2(.)(ω)). Since r(ΦM1(.)(ω)) > 1, we can choose ξ and η¯ suﬃciently small,ω
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2π
3 )) < 1. Parameters are d = 0.02 day−1, δ = 0.24 day−1, N = 1000 virions/cell, c = 2.4 day−1,
k = 2.4× 10−5 virionsmm3 day−1, nrt (t) = 0.4− 0.3cos(3t) and λ = 1 cellmm−3 day−1.
which ensures η small enough, such that r(ΦM1(.)−ηM2(.)(ω)) > 1. It follows that μ2 > 0. Choose t¯  t1 and a small number
α > 0 such that
(
T˘ ∗(t¯)
V˘ (t¯)
)
 α
(
p1(0)
p2(0)
)
.
By the comparison principle we get
(
T ∗(t)
V (t)
)

(
T˘ ∗(t)
V˘ (t)
)
 αeμ2(t−t¯)
(
p1(t − t¯)
p2(t − t¯)
)
 αeμ2(t−t¯)
(
mintt¯ p1(t − t¯)
mintt¯ p2(t − t¯)
)
, t  t¯.
Hence
lim
t→∞ T
∗(t) = ∞, lim
t→∞ V (t) = ∞.
This is a contradiction to
0 T ∗(t) , 0 V (t) .
Thus we get Ws(E1) ∩ X0 = ∅. Clearly, each orbit in M∂ converges to E1, and hence E1 is acyclic in M∂ .
By Lemma 2.2, P is uniformly persistent with respect to (X0, ∂ X0). It follows from [3, Theorem 3.1.1] that the solution
of (1.2) is uniformly persistent. Thus we have ﬁnished the proof of Theorem 2.2. 
In order to see the behavior of each population vividly, we have done some simulation work. Numerical integration
was carried out the Runge–Kutta method in Matlab 6.5. Most of these values are taken from Perelson and Nelson [6]. Let
d = 0.02 day−1, δ = 0.24 day−1, N = 1000 virions/cell, c = 2.4 day−1, k = 2.4 × 10−5 virionsmm3 day−1. We choose the
periodic drug eﬃcacy of the RTIs nrt(t) as nrt(t) = 0.4 − 0.3cos(3t), then the period of system (1.2) is ω = 2π3 . The initial
values are T (0) = 180 cellsmm−3, T ∗(0) = 3.6 cellsmm−3, V (0) = 134 cellsmm−3.
We choose λ = 1 cellmm−3 day−1. Numerical calculation yields r(ΦM1(.)( 2π3 )) = 0.7110, which is less than unity. Then
Theorem 2.1 indicates that the disease-free equilibrium of system (1.2), i.e., E1(50,0,0), is globally asymptotically stable.
The concentration of uninfected T cells (T (t)), infected T cells (T ∗(t)) and virus (V (t)) are plotted against time in Fig. 1, and
it further conﬁrms eradication of the viral loads in the body.
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In this section we shall investigate existence and stability of a positive periodic solution of system (1.2). For convenience
of description we ﬁrst present the following lemma from [3, Theorem 1.3.6]. Let X, X0, ∂ X0 be as aforementioned.
Lemma 3.1. Let S : X → X be a continuous map with S(X0) ⊂ X0 . Assume
(1) S : X → X is point dissipative;
(2) S is compact; or alternatively, S is α-condensing and γ +(U ) is strongly bounded in X0 if U is strongly bounded in X0;
(3) S is uniformly persistent with respect to (X0, ∂ X0).
Then there exists a global attractor A0 for S in X0 that attracts strongly bounded sets in X0 , and S has a coexistence state x0 ∈ A0 .
Theorem 3.1. Suppose r(ΦM1(.)(ω)) > 1, then the system (1.2) admits a positive ω-periodic solution which is globally asymptotically
stable.
Proof. It follows from Proposition 2.1 that solutions of (1.2) are uniformly and ultimately bounded. Thus the semiﬂow P is
point dissipative on R3+ , and P : R3+ → R3+ is compact. By Theorem 2.2, P is uniformly persistent with respect to (X0, ∂ X0).
Then it follows from Lemma 3.1 that the Poincaré map P has a ﬁxed point (T˜ , T˜ ∗, V˜ ) ∈ Int(R3+). Hence, u(t, (T˜ , T˜ ∗, V˜ )) ∈
Int(R3+), for all t  0. Thus (T˜ (t), T˜ ∗(t), V˜ (t)) is a positive ω-periodic solution of system (1.2) due to the deﬁnition of the
semiﬂow P .
Let X˜(t) = (T˜ (t), T˜ ∗(t), V˜ (t)) be positive ω-periodic solution of the system (1.2), and (T (t), T ∗(t), V (t)) any solution of
system (1.2) initiating from nonnegative initial values.
Deﬁne the following Lyapunov function
M
(
T , T ∗, V
)= ∣∣T (t) − T˜ (t)∣∣+ ∣∣T ∗(t) − T˜ ∗(t)∣∣+ 1
N
∣∣V (t) − V˜ (t)∣∣.
Then the D+M(t) following system (1.2) is
D+M(t) = sign(T (t) − T˜ (t)){−d(T (t) − T˜ (t))− K (t)T V + K (t)T˜ (t)V˜ (t)}
+ sign(T ∗(t) − T˜ ∗(t)){K (t)T V − δT ∗ − K (t)T˜ (t)V˜ (t) + δ T˜ ∗(t)}
+ sign(V (t) − V˜ (t))
{
δT ∗ − δ T˜ ∗(t) − c
N
(
V (t) − V˜ (t))
}
−d∣∣T (t) − T˜ (t)∣∣− c
N
∣∣V (t) − V˜ (t)∣∣.
Let μ =min{d, c/N}, then it follows that
D+M(t)−μ{∣∣T (t) − T˜ (t)∣∣+ ∣∣V (t) − V˜ (t)∣∣}.
Integrating the above inequality from t¯ to +∞, we obtain
M(t) + μ
+∞∫
t¯
(∣∣T (s) − T˜ (s)∣∣+ ∣∣V (s) − V˜ (s)∣∣)ds < M(t¯).
Provided that t > t¯ , it follows that
sup
t→+∞
+∞∫
t¯
(∣∣T (s) − T˜ (s)∣∣+ ∣∣V (s) − V˜ (s)∣∣)ds M(t¯)
μ
< +∞.
Then, we have
lim
t→∞
∣∣T (t) − T˜ (t)∣∣= 0, lim
t→+∞
∣∣T ∗(t) − T˜ ∗(t)∣∣= 0, lim
t→+∞
∣∣V (t) − V˜ (t)∣∣= 0.
That is to say, the positive period solution (T˜ (t), T˜ ∗(t), V˜ (t)) is globally asymptotically stable. This completes the proof. 
66 Y. Yang, Y. Xiao / J. Math. Anal. Appl. 361 (2010) 59–68Remark 3.1. Cyclic pattern of physiological changes or changes in activity in living organisms, most often synchronize with
daily, monthly, or annual cyclical changes in the environment. Hence it is reasonable to consider the model (1.2) with time
dependent coeﬃcients. The model is as follows.⎧⎪⎪⎪⎪⎪⎪⎨
⎪⎪⎪⎪⎪⎪⎩
dT
dt
= λ(t) − d(t)T − K (t)T V ,
dT ∗
dt
= K (t)T V − δ(t)T ∗,
dV
dt
= N(t)δ(t)T ∗ − c(t)V ,
(3.1)
where coeﬃcients are nonnegative and periodic functions. Since the period of the drug eﬃcacy might be dose interval,
which could be several days, we can choose the maximal period of the coeﬃcient functions as a common period of the
system (3.1).
We denote by Aω(g) = 1/ω
∫ w
0 g(t)dt the average value of any ω-periodic continuous function g(t). Assume that
Aω(λ) > 0, Aω(d) > 0. Meanwhile, we denote by T¯ (t) the globally asymptotically stable periodic solution of the equation
T˙ (t) = λ(t) − d(t)T , where T¯ (t) = ∫∞0 λ(t − s)e−
∫ s
0 d(t−σ)dσ ds. Therefore, (T¯ (t),0,0) is the disease-free periodic solution of
the system (3.1). We give the threshold parameter r(ΦM¯1(.)(ω)), where
M¯1(t) =
( −δ(t) K (t)T¯ (t)
N(t)δ(t) −c(t)
)
.
We have the following results for the system (3.1).
Theorem 3.2. If r(ΦM¯1(.)(ω)) < 1, then limt→∞(T (t) − T¯ (t)) = 0, limt→∞ T ∗(t) = 0, limt→∞ V (t) = 0.
Theorem 3.3. If r(ΦM¯1(.)(ω)) > 1, then the system (3.1) is uniformly persistent, and admits a positive periodic solution which is
globally asymptotically stable.
The proofs of Theorems 3.2 and 3.3 are similar to those obtained for the system (1.2), hence we omit them.
Remark 3.2. Huang et al. [19] proposed an HIV viral dynamic model with time-varying eﬃcacies of PI(s) and RTI(s) to
describe the antiviral responses. They investigated the analytic properties of the model on the basis of the fact that the drug
eﬃcacies tend to constants as time goes to inﬁnity. As mentioned in the introduction, (plasm) drug concentration, and hence
drug eﬃcacies, might vary periodically. We then investigate the model proposed in [19] with the periodic drug eﬃcacies.
By using similar methods we theoretically examine the model and get the threshold value and important conclusions. For
simplicity we don’t include the logistic term for dynamics of uninfected T cells. So the model equations are as follows.
⎧⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎨
⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎩
dT
dt
= λ − dT − [1− γ (t)]kT V I ,
dT ∗
dt
= [1− γ (t)]kT V I − δT ∗,
dV I
dt
= (1− η0)
[
1− η(t)]NδT ∗ − cV I ,
dVNI
dt
= {1− (1− η0)[1− η(t)]}NδT ∗ − cVNI ,
(3.2)
where T , T ∗, V I and VNI are numbers of target uninfected cells, infected cells, infectious virions and noninfectious virions,
respectively; the functions γ (t) and η(t) are the drug eﬃcacies of RTI(s) and PI(s), respectively, which are nonnegative and
periodic functions with common period ω. Further, assume 1ω
∫ ω
0 γ (t)dt > 0 and
1
ω
∫ ω
0 η(t)dt > 0. η0 is the proportion of
noninfectious virus in the total virus pool before initiation of regimen. Other constants k, λ, d, δ, N , and c are the same as
those in system (1.1).
We denote by K (t) = [1− γ (t)]k, L(t) = 1− η(t). We give the threshold parameter r(ΦM10(.)(ω)), where
M10(t) =
⎛
⎝
−δ λd K (t) 0
(1− η0)L(t)Nδ −c 0
η0L(t)Nδ 0 −c
⎞
⎠ .
We have the following results for the system (3.2).
Y. Yang, Y. Xiao / J. Math. Anal. Appl. 361 (2010) 59–68 67Fig. 2. The periodic behavior of model (1.2). Parameters are d = 0.02 day−1, δ = 0.24 day−1, N = 1000 virions/cell, c = 2.4 day−1, k = 2.4 × 10−5 viri-
onsmm3 day−1, nrt (t) = 0.4− 0.3cos(3t) and λ = 10 cellsmm−3 day−1.
Theorem 3.4. If r(ΦM10(.)(ω)) < 1, then limt→∞(T (t) − T¯ ) = 0, limt→∞ T ∗(t) = 0, limt→∞ V I (t) = 0, limt→∞ VNI (t) = 0.
Theorem 3.5. If r(ΦM10(.)(ω)) > 1, then the system (3.2) is uniformly persistent, and there exists a positive periodic solution which is
globally asymptotically stable.
The proofs of Theorems 3.4 and 3.5 are similar to those obtained for the system (1.2) substituting M10(t) for M1(t), and
M20(t) for M2(t), where
M20(t) =
⎛
⎝
0 K (t) 0
0 0 0
0 0 0
⎞
⎠ .
We then omit them.
Note that when the drug eﬃcacies γ (t) and η(t) are constants, the threshold parameter of the system (3.2) gives
kλN
cd
(1− η0)
[
1− γ (t)][1− η(t)].
This is in accordance with that for the system examined in [19] in the absence of the logistic term for the uninfected T cells.
We choose similar parameter set and do numerical simulations to show the persistence of disease. Here we let λ =
10 cellsmm−3 day−1. Numerical calculation yields r(ΦM1(.)( 2π3 )) = 2.1976 > 1, then Theorems 2.2 and 3.1 indicate that
system (1.2) admits a positive periodic solution which is globally asymptotically stable. Fig. 2(a) conﬁrms the existence
of the positive periodic solution. Using parameter set we could calculate that the equilibrium level of virions is 3333.3 if
without considering drug therapy. Fig. 2(b) shows that maximum virus load does not exceed the above equilibrium level,
and hence drug therapy greatly decreases the level of viral loads in the body.
4. Conclusions and discussions
In this paper, we have established and analyzed a time-dependent HIV model incorporating the effects of drug therapy.
Drug concentration varies during dose intervals, hence drug eﬃcacy changes periodically. Our model is then a periodic one
with periodic function K (t) representing k(1−nrt(t)) for convenience. We have obtained a threshold parameter r(ΦM1(.)(ω)),
which determines the extinction and the uniform persistence of the disease. Our main results show that the disease-free
equilibrium of system (1.2), E1(λ/d,0,0), is globally asymptotically stable if r(ΦM1(.)(ω)) < 1, whilst the disease is persistent
if r(ΦM1(.)(ω)) > 1, and meanwhile there exists a positive periodic solution which is globally asymptotically stable.
If there is no drug therapy, i.e., nrt(t) = 0 in system (1.2), then system (1.2) degenerates to the system proposed by
Bonhoeffer et al. in [1] with constant coeﬃcients, and the threshold parameter r(ΦM1(.)(ω)) then yields kλN/(cd), which is
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state (λ/d,0,0) is globally asymptotically stable, whilst if R0 > 1, in addition to the disease-free state, which is unstable,
there is a “chronic disease” steady state which is globally asymptotically stable. Thus our result is in agreement with that for
the system with constant coeﬃcients. Numerical simulations indicate that when incorporating drug therapy, the maximum
virus load in human body is much lower than the equilibrium level of viral load without drug therapy. Therefore, drug
therapy does not alter dynamical behavior of the system, but results in viral loads decline.
When drug eﬃcacies, γ (t) representing the eﬃcacy of RTIs and η(t) the eﬃcacy of PIs, are time-varying, Huang et al. [19]
gave the basic reproduction number. Local stability analysis of the uninfected state and existence of the infected state were
obtained on the basis of the fact that drug eﬃcacies approach constants as time goes to inﬁnity. Note that our model (3.2)
is formulated to represent periodic varies of the drug eﬃcacies. The detailed theoretical investigation for the viral dynamic
model with periodic drug eﬃcacies has also been obtained. We get the threshold parameter and prove that the disease dies
out if the threshold is less than unity, otherwise the disease persists and the system admits a periodic solution which is
globally asymptotically stable.
T cells can also be created by proliferation of existing T cells [7,8]. In model (1.1) the authors represented the proliferation
by a logistic function [6,9–15]. Our model formulated here ignores the proliferation of existing T cells. Hence, the inclusion
of the logistic part is a natural extension, which formulates our further work. Further the dynamics of the drug could also
be included in our model, which will be another further work.
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